Literature DB >> 33904138

A case report of simultaneous autoimmune and COVID-19 encephalitis.

Fakhri Allahyari1, Ramin Hosseinzadeh2, Javad Hosseini Nejad1, Mohammad Heiat3, Reza Ranjbar4.   

Abstract

COVID-19 encephalitis is a rare condition usually presenting with altered mental status. Simultaneous presence of anti-NMDAR antibody and SARS-CoV-2 virus in CSF is a very rare condition described in a few case reports so far. On the other hand, brain edema is an unusual presentation of anti-NMDAR encephalitis. Herein, we reported a case with simultaneous detection of anti-NMDAR antibody and SARS-CoV-2 virus in her cerebrospinal fluid (CSF) presenting with brain edema, altered mental status, seizures, and respiratory symptoms.

Entities:  

Keywords:  Autoimmune; COVID-19; Encephalitis; Seizures

Mesh:

Year:  2021        PMID: 33904138      PMCID: PMC8075017          DOI: 10.1007/s13365-021-00978-w

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   3.739


Case report

An 18-year-old girl with no medical history was admitted on June 22, 2020, to the emergency room of Ghaem hospital, Karaj, Iran, with generalized tonic–clonic seizures. She had a 3-week history of mood change as depression and anhedonia accompanied by lack of concentration, low-grade fever, dry coughs, and shortness of breath. Her respiratory symptoms were aggravated after the initiation of seizures. Despite the initiation of sodium valproate, she had a second episode of tonic–clonic seizures. At initial evaluations, she had a 38.7 °C axillary fever, 100/60 mmHg blood pressure, pulse rate of 106, respiratory rate of 20, oxygen saturation of 90%, bilateral pulmonary crackles in lower lung zones, a confused state, minor meningismus, and neck stiffness. She did not have any other neurological symptoms such as papillary edema, cranial nerve palsy, and focal neurological deficit on the neurological exam. Initial brain and lung CT scans are showed below (Fig. 1).
Fig. 1

Pictures 1–3 show peripheral ground-glass opacities and consolidations in lower lung zones. Pictures 4–5 show generalized brain edema

Pictures 1–3 show peripheral ground-glass opacities and consolidations in lower lung zones. Pictures 4–5 show generalized brain edema Meanwhile, her level of consciousness was deteriorated so she was undergone lumbar puncture and transmitted to ICU and started on broad spectrum antibiotics and acyclovir. CBC showed a WBC of 13,900 with neutrophilia (87%) and lymphopenia(10%). C-reactive protein was 2+ . According to these findings, she was started on Remdesivir, Lopinavir/Ritonavir, and interferon b1a (Resigen). A day after, CSF analysis came back as appearance: semi turbid, color: light pink, WBC: 27, RBC: 1997, lymphocytes: 93%, PMN: 7%, glucose: 55 mg/dL, protein: 241 mg/dL. HSV1&2 DNA PCR also came back negative in CSF. No improvement in mental status and level of consciousness was seen in first 3 days but the seizures were controlled. At this time, an MRI was performed to have a closer look at the brain which came back normal and the brain edema was resolved (Fig. 2) so, she did not receive any specific treatments for the brain edema such as mannitol or hypertonic saline. Interestingly, her CSF PCR came back weakly positive for COVID-19. NMDAR antibody in CSF also came back positive in accordance with the result of indirect (transfected cells) immunofluorescence test (IIFT kit, EUROIMMUN Co., Lubeck, Germany). Therefore, she was started on IVIG (25 g/day). Her consciousness started to improve after 48 h of IVIG treatment. One week after admission, the blood and CSF cultures came back negative. Therefore, she was stopped on intravenous antibiotics and started on methylprednisolone (2.5 g/5 days) and then tapered using oral corticosteroids. In the same time, her IgM for COVID-19 came back positive. After 2 weeks of admission, she was discharged from ICU and neurology service with normal consciousness. During hospitalization, her respiratory symptoms were mild and she did not show severe problems with oxygenation; therefore, there was no need to mechanical ventilation for the patient. After 2 months of hospitalization for completing COVID-19 treatments, she was discharged with full recovery.
Fig. 2

Normal brain MRI. Pictures 1–6 show the brain edema has been resolved

Normal brain MRI. Pictures 1–6 show the brain edema has been resolved

Discussion

Neurological symptoms of COVID-19 are caused by nervous system directly affected by the virus or immune-mediated para-infectious conditions (Romero-Sánchez et al. 2020; Helms et al. 2020; Moriguchi et al. 2020). Anti-NMDAR encephalitis has been reported in few cases of COVID-19 before (Panariello et al. 2020; Monti et al. 2020; Burr et al. 2020). On the other hand, brain edema which is an unusual finding in anti-NMDAR encephalitis has also been rarely reported in COVID-19 patients (Coolen et al. 2020; Kadono et al. 2020). In this case, we had simultaneous presence of SARS-CoV-2 RNA and NMDAR antibody in CSF accompanied by generalized brain edema which is rare, and to our knowledge, it has never been addressed so far. Although many new insights have been provided in regard to the pathogenesis of COVID-19, precise interactions between virus-host cells remain unclear. Indeed, the integration of new emerging sciences will help us to fight COVID-19 disease and related complications more efficiently in the future. (Mohammadpour et al. 2021; Mirzaei et al. 2020a; Heiat et al. 2021; Mirzaie et al. 2020b).
  12 in total

1.  Integrative role of traditional and modern technologies to combat COVID-19.

Authors:  Mohammad Heiat; Mohammad-Reza Hashemi-Aghdam; Fatemeh Heiat; Mona Rastegar Shariat Panahi; Hossein Aghamollaei; Mehrdad Moosazadeh Moghaddam; Thozhukat Sathyapalan; Reza Ranjbar; Amirhossein Sahebkar
Journal:  Expert Rev Anti Infect Ther       Date:  2020-08-23       Impact factor: 5.091

2.  Early postmortem brain MRI findings in COVID-19 non-survivors.

Authors:  Tim Coolen; Valentina Lolli; Niloufar Sadeghi; Antonin Rovai; Nicola Trotta; Fabio Silvio Taccone; Jacques Creteur; Sophie Henrard; Jean-Christophe Goffard; Olivier Dewitte; Gilles Naeije; Serge Goldman; Xavier De Tiège
Journal:  Neurology       Date:  2020-06-16       Impact factor: 9.910

Review 3.  A contemporary review on pathogenesis and immunity of COVID-19 infection.

Authors:  Rasoul Mirzaei; Sajad Karampoor; Mohammad Sholeh; Pouya Moradi; Reza Ranjbar; Faezeh Ghasemi
Journal:  Mol Biol Rep       Date:  2020-06-29       Impact factor: 2.316

4.  Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19.

Authors:  Giulia Monti; Giada Giovannini; Andrea Marudi; Roberta Bedin; Alessandra Melegari; Anna Maria Simone; Mario Santangelo; Alessandro Pignatti; Elisabetta Bertellini; Tommaso Trenti; Stefano Meletti
Journal:  Seizure       Date:  2020-07-15       Impact factor: 3.184

5.  Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient: A case report.

Authors:  Adelaide Panariello; Roberta Bassetti; Anna Radice; Roberto Rossotti; Massimo Puoti; Matteo Corradin; Mauro Moreno; Mauro Percudani
Journal:  Brain Behav Immun       Date:  2020-05-23       Impact factor: 7.217

6.  Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry.

Authors:  Carlos Manuel Romero-Sánchez; Inmaculada Díaz-Maroto; Eva Fernández-Díaz; Álvaro Sánchez-Larsen; Almudena Layos-Romero; Jorge García-García; Esther González; Inmaculada Redondo-Peñas; Ana Belén Perona-Moratalla; José Antonio Del Valle-Pérez; Julia Gracia-Gil; Laura Rojas-Bartolomé; Inmaculada Feria-Vilar; María Monteagudo; María Palao; Elena Palazón-García; Cristian Alcahut-Rodríguez; David Sopelana-Garay; Yóscar Moreno; Javaad Ahmad; Tomás Segura
Journal:  Neurology       Date:  2020-06-01       Impact factor: 9.910

7.  Neurologic Features in Severe SARS-CoV-2 Infection.

Authors:  Julie Helms; Stéphane Kremer; Hamid Merdji; Raphaël Clere-Jehl; Malika Schenck; Christine Kummerlen; Olivier Collange; Clotilde Boulay; Samira Fafi-Kremer; Mickaël Ohana; Mathieu Anheim; Ferhat Meziani
Journal:  N Engl J Med       Date:  2020-04-15       Impact factor: 91.245

8.  N-Methyl-d-Aspartate Receptor Encephalitis Associated With COVID-19 Infection in a Toddler.

Authors:  Tyler Burr; Christopher Barton; Elizabeth Doll; Arpita Lakhotia; Michael Sweeney
Journal:  Pediatr Neurol       Date:  2020-10-09       Impact factor: 3.372

Review 9.  A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19).

Authors:  Amir Mirzaie; Mehrdad Halaji; Farhad Safarpoor Dehkordi; Reza Ranjbar; Hassan Noorbazargan
Journal:  Complement Ther Clin Pract       Date:  2020-06-17       Impact factor: 2.446

Review 10.  An updated review of the association of host genetic factors with susceptibility and resistance to COVID-19.

Authors:  Somayeh Mohammadpour; Amir Torshizi Esfahani; Mehrdad Halaji; Mina Lak; Reza Ranjbar
Journal:  J Cell Physiol       Date:  2020-06-15       Impact factor: 6.513

View more
  15 in total

Review 1.  The pathogenesis of neurologic symptoms of the postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection.

Authors:  Brian Walitt; Tory P Johnson
Journal:  Curr Opin Neurol       Date:  2022-06-01       Impact factor: 6.283

Review 2.  Autoimmune Encephalitis in COVID-19 Infection: Our Experience and Systematic Review of the Literature.

Authors:  Adina Stoian; Mircea Stoian; Zoltan Bajko; Smaranda Maier; Sebastian Andone; Roxana Adriana Cioflinc; Anca Motataianu; Laura Barcutean; Rodica Balasa
Journal:  Biomedicines       Date:  2022-03-25

3.  Comments on "CSF-Confirmed SARS-CoV-2 Acute Encephalitis": SARS-CoV-2-Associated Encephalitis Is Autoimmune Rather Than Infectious.

Authors:  Josef Finsterer; Fulvio Alexandre Scorza; Ana Claudia Fiorini
Journal:  J Clin Neurol       Date:  2022-01       Impact factor: 3.077

Review 4.  Immune-mediated neurological syndrome in SARS-CoV-2 infection: a review of literature on autoimmune encephalitis in COVID-19.

Authors:  Alvin Oliver Payus; Mohammad Saffree Jeffree; May Honey Ohn; Hui Jan Tan; Azliza Ibrahim; Yuen Kang Chia; Azman Ali Raymond
Journal:  Neurol Sci       Date:  2021-12-01       Impact factor: 3.830

5.  Neurological symptoms of COVID-19 infection; a cross-sectional study on hospitalized COVID-19 patients in Iran.

Authors:  Javad Hosseini Nejad; Fakhri Allahyari; Ramin Hosseinzadeh; Mohammad Heiat; Reza Ranjbar
Journal:  Clin Neurol Neurosurg       Date:  2021-10-11       Impact factor: 1.876

6.  A case-based systematic review on the SARS-COVID-2-associated cerebrovascular diseases and the possible virus routes of entry.

Authors:  Ali Lashkari; Reza Ranjbar
Journal:  J Neurovirol       Date:  2021-09-21       Impact factor: 2.643

7.  COVID-19, Anti-NMDA Receptor Encephalitis and MicroRNA.

Authors:  Hsiuying Wang
Journal:  Front Immunol       Date:  2022-03-22       Impact factor: 7.561

Review 8.  Neuroimmune disorders in COVID-19.

Authors:  Helena Ariño; Rosie Heartshorne; Benedict D Michael; Timothy R Nicholson; Angela Vincent; Thomas A Pollak; Alberto Vogrig
Journal:  J Neurol       Date:  2022-03-30       Impact factor: 6.682

9.  Guillain-Barré syndrome associated with COVID-19: a case report study.

Authors:  Javad Hosseini Nejad; Mohammad Heiat; Mohammad Javad Hosseini; Fakhri Allahyari; Ali Lashkari; Raheleh Torabi; Reza Ranjbar
Journal:  J Neurovirol       Date:  2021-05-27       Impact factor: 3.739

10.  Unprovoked serotonin syndrome-like presentation of SARS-CoV-2 infection: A small case series.

Authors:  Philip Keith; Marc Saint-Jour; Frank Pusey; Jeremy Hodges; Farid Jalali; L Keith Scott
Journal:  SAGE Open Med Case Rep       Date:  2021-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.